Literature DB >> 28919634

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.

P Boddu1, J Jorgensen2, H Kantarjian1, G Borthakur1, T Kadia1, N Daver1, Y Alvarado1, N Pemmaraju1, P Bose1, K Naqvi1, M Yilmaz1, S Pierce1, M Brandt1, C D DiNardo1, E J Jabbour1, M Konopleva1, G Garcia-Manero1, J Cortes1, F Ravandi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28919634     DOI： 10.1038/leu.2017.285

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Competing risk of death: an important consideration in studies of older adults.

Authors:  Sarah D Berry; Long Ngo; Elizabeth J Samelson; Douglas P Kiel
Journal:  J Am Geriatr Soc       Date:  2010-03-22       Impact factor: 5.562

2.  Competing risks.

Authors:  Jason Fine; Bo Henry Lindqvist
Journal:  Lifetime Data Anal       Date:  2014-03-18       Impact factor: 1.588

3.  Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines.

Authors:  Aaron N Nguyen; Paul W Hollenbach; Normand Richard; Antonio Luna-Moran; Helen Brady; Carla Heise; Kyle J MacBeth
Journal:  Lung Cancer (Auckl)       Date:  2010-09-09

4.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Ulrich Germing; Guillermo Sanz; Alan F List; Steven Gore; John F Seymour; Hervé Dombret; Jay Backstrom; Linda Zimmerman; David McKenzie; C L Beach; Lewis R Silverman
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

5.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Authors:  Hagop M Kantarjian; Xavier G Thomas; Anna Dmoszynska; Agnieszka Wierzbowska; Grzegorz Mazur; Jiri Mayer; Jyh-Pyng Gau; Wen-Chien Chou; Rena Buckstein; Jaroslav Cermak; Ching-Yuan Kuo; Albert Oriol; Farhad Ravandi; Stefan Faderl; Jacques Delaunay; Daniel Lysák; Mark Minden; Christopher Arthur
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

Review 6.  Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant.

Authors:  Jeffrey E Lancet; Sergio Giralt
Journal:  J Natl Compr Canc Netw       Date:  2008-11       Impact factor: 11.908

7.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

8.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

9.  Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.

Authors:  Farhad Ravandi; Jeffrey Jorgensen; Gautam Borthakur; Elias Jabbour; Tapan Kadia; Sherry Pierce; Mark Brandt; Sa Wang; Sergej Konoplev; Xuemei Wang; Xuelin Huang; Naval Daver; Courtney DiNardo; Michael Andreeff; Marina Konopleva; Zeev Estrov; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  Cancer       Date:  2016-09-22       Impact factor: 6.860

10.  Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.

Authors:  Sylvie D Freeman; Paul Virgo; Steve Couzens; David Grimwade; Nigel Russell; Robert K Hills; Alan K Burnett
Journal:  J Clin Oncol       Date:  2013-09-23       Impact factor: 44.544
View more
  14 in total

1.  MRD evaluation of AML in clinical practice: are we there yet?

Authors:  Sylvie D Freeman; Christopher S Hourigan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 2.  Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.

Authors:  Roland B Walter; Yishai Ofran; Agnieszka Wierzbowska; Farhad Ravandi; Christopher S Hourigan; Lok Lam Ngai; Adriano Venditti; Francesco Buccisano; Gert J Ossenkoppele; Gail J Roboz
Journal:  Leukemia       Date:  2021-03-23       Impact factor: 11.528

3.  Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.

Authors:  Keith W Pratz; Brian A Jonas; Vinod Pullarkat; Christian Recher; Andre C Schuh; Michael J Thirman; Jacqueline S Garcia; Courtney D DiNardo; Vladimir Vorobyev; Nicola S Fracchiolla; Su-Peng Yeh; Jun Ho Jang; Muhit Ozcan; Kazuhito Yamamoto; Arpad Illes; Ying Zhou; Monique Dail; Brenda Chyla; Jalaja Potluri; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2021-12-15       Impact factor: 44.544

4.  Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis.

Authors:  Nicholas J Short; Chenqi Fu; Donald A Berry; Roland B Walter; Sylvie D Freeman; Christopher S Hourigan; Xuelin Huang; Graciela Nogueras Gonzalez; Hyunsoo Hwang; Xinyue Qi; Hagop Kantarjian; Shouhao Zhou; Farhad Ravandi
Journal:  Leukemia       Date:  2022-10-19       Impact factor: 12.883

5.  Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.

Authors:  Gerwin Huls; Dana A Chitu; Thomas Pabst; Saskia K Klein; Georg Stussi; Laimonas Griskevicius; Peter J M Valk; Jacqueline Cloos; Arjan A van de Loosdrecht; Dimitri Breems; Danielle van Lammeren-Venema; Isabelle van Zeventer; Rinske Boersma; Mojca Jongen-Lavrencic; Martin Fehr; Mels Hoogendoorn; Markus G Manz; Maaike Söhne; Rien van Marwijk Kooy; Dries Deeren; Marjolein W M van der Poel; Marie Cecile Legdeur; Lidwine Tick; Yves Chalandon; Emanuele Ammatuna; Sabine Blum; Bob Löwenberg; Gert J Ossenkoppele
Journal:  Blood Adv       Date:  2020-09-22

Review 6.  Evaluating measurable residual disease in acute myeloid leukemia.

Authors:  Farhad Ravandi; Roland B Walter; Sylvie D Freeman
Journal:  Blood Adv       Date:  2018-06-12

7.  Acute promyelocytic leukemia derived extracellular vesicles conserve PML-RARα transcript from storage-inflicted degradation: a stable diagnosis tool in APL patients.

Authors:  Mohieddin Barzegar; Mehdi Allahbakhshian Farsani; Mohammad Rafiee; Vahid Amiri; Sayeh Parkhihdeh; Fariba Rad; Mohammad Hossein Mohammadi
Journal:  Ann Hematol       Date:  2021-07-08       Impact factor: 3.673

8.  Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.

Authors:  Abhishek Maiti; Courtney D DiNardo; Sa A Wang; Jeffrey Jorgensen; Tapan M Kadia; Naval G Daver; Nicholas J Short; Musa Yilmaz; Naveen Pemmaraju; Gautam Borthakur; Prithviraj Bose; Ghayas C Issa; Alessandra Ferrajoli; Elias J Jabbour; Nitin Jain; Guillermo Garcia-Manero; Maro Ohanian; Koichi Takahashi; Guillermo Montalban-Bravo; Lucia Masarova; Jan A Burger; Philip A Thompson; Srdan Verstovsek; Koji Sasaki; Michael Andreeff; Caitlin R Rausch; Kathryn S Montalbano; Sherry Pierce; Wei Qiao; Jing Ning; Hagop M Kantarjian; Marina Y Konopleva; Farhad Ravandi
Journal:  Blood Adv       Date:  2021-04-13

9.  Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.

Authors:  Catia Simoes; Bruno Paiva; David Martínez-Cuadrón; Juan-Miguel Bergua; Susana Vives; Lorenzo Algarra; Mar Tormo; Pilar Martinez; Josefina Serrano; Pilar Herrera; Fernando Ramos; Olga Salamero; Esperanza Lavilla; Cristina Gil; Jose-Luis Lopez; Maria-Belen Vidriales; Jorge Labrador; Jose-Francisco Falantes; María-José Sayas; Rosa Ayala; Joaquin Martinez-Lopez; Sara Villar; Maria-Jose Calasanz; Felipe Prosper; Jesús F San-Miguel; Miguel Ángel Sanz; Pau Montesinos
Journal:  Blood Adv       Date:  2021-02-09

Review 10.  A precision medicine approach to management of acute myeloid leukemia in older adults.

Authors:  Shristi Upadhyay Banskota; Nabin Khanal; Vijaya Raj Bhatt
Journal:  Curr Opin Oncol       Date:  2020-11       Impact factor: 3.915
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.